<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025865</url>
  </required_header>
  <id_info>
    <org_study_id>21-486</org_study_id>
    <nct_id>NCT05025865</nct_id>
  </id_info>
  <brief_title>HA35 Acute Alcohol Study</brief_title>
  <official_title>Mechanisms by Which HA35 Regulates Muscle Protein Homeostasis in Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible subjects will be asked to take a placebo/treatment capsule for a total of 3 days and&#xD;
      then participate in a study visit on the fourth day. This study visit will include a medical&#xD;
      exam, clinical labs, questionnaires, body composition measurements, and urine and stool&#xD;
      collections. Additionally, participants will consume a sugar cocktail to measure their gut&#xD;
      permeability, participate in an acute ethanol challenge, and undergo two muscle biopsies. The&#xD;
      study will take approximately 3-4 hours and a designated driver will need to drive the&#xD;
      participant home. On the fifth day, you will be asked to return to drop of the 24-hour urine&#xD;
      collection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interested subjects will be assessed for eligibility and a written informed consent will be&#xD;
      obtained. The screening visit will consist of a medical exam, clinical labs (if not available&#xD;
      in medical record), and questionnaires. Those who pass the screening will be eligible for a&#xD;
      baseline visit (may be combined with screening if appropriate labs are already done). The&#xD;
      baseline visit will include collection of blood, urine, and stool samples, body composition&#xD;
      measurements, and randomization into either HA35 or placebo groups. Patients will be&#xD;
      instructed to take the HA35 or placebo daily in the morning before breakfast 3 days prior to&#xD;
      the day 4 visit. Patients will be informed that they will need to have a driver that is known&#xD;
      to them for the day 4 visit. In the morning of the day 4 visit, confirmation of a driver will&#xD;
      occur prior to starting study procedures. During the day 4 visit, patients will have an acute&#xD;
      ethanol challenge where they will need to consume 2mL/kg of vodka in 100mL of juice in under&#xD;
      60 minutes. Muscle biopsies will be collected before and after the challenge and blood will&#xD;
      be collected throughout the day. In addition, patients will be given&#xD;
      lactulose/mannitol/sucralose/sucrose cocktail to measure gut permeability. The costs of any&#xD;
      of these tests/procedures will not be billed to the patient and will be covered by the&#xD;
      department. The participant will not be responsible for any costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline to day 4</time_frame>
    <description>change in units/liter (U/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline to day 4</time_frame>
    <description>change in units/liter (U/L)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>HA35 Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 study participants will be given a placebo capsule to take once per day in the morning with breakfast for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA35 Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 study participants will be given an HA35 capsule to take once per day in the morning with breakfast for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate</intervention_name>
    <description>Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.</description>
    <arm_group_label>HA35 Treatment Group</arm_group_label>
    <other_name>HA35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo will be given in capsule form to study participants.</description>
    <arm_group_label>HA35 Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alcohol consumption of less than 7 drinks per week for women and less than 14 drinks&#xD;
             per week for men&#xD;
&#xD;
          -  Ability to understand and willingness to provide written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known chronic illness including but not limited to cancer (except non-melanoma&#xD;
             skin cancer)&#xD;
&#xD;
          -  Poorly controlled diabetes (Hemoglobin A1c &gt;9.5 g/dl)&#xD;
&#xD;
          -  Untreated hyper/hypothyroidism&#xD;
&#xD;
          -  Uncontrolled hypertension or hypercholesterolemia&#xD;
&#xD;
          -  End-stage renal disease&#xD;
&#xD;
          -  Liver disease of any etiology&#xD;
&#xD;
          -  Coronary artery disease or stroke&#xD;
&#xD;
          -  Active intravenous drug use&#xD;
&#xD;
          -  History of gastric bypass&#xD;
&#xD;
          -  Medications known to alter muscle protein synthesis (systemic corticosteroids,&#xD;
             tamoxifen, high dose estrogen, testosterone, or anabolic steroids)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Past alcohol use disorder&#xD;
&#xD;
          -  Abnormal clotting factors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Srinivasan Dasarathy, MD</last_name>
    <phone>216-318-7010</phone>
    <email>dasaras@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Bellar</last_name>
    <email>bellara@ccf.org</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Srinivasan Dasarathy</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

